Golden State Wealth Management LLC Takes Position in Johnson & Johnson (NYSE:JNJ)

Golden State Wealth Management LLC purchased a new position in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 4,203 shares of the company’s stock, valued at approximately $608,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Centerline Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $213,000. Live Oak Private Wealth LLC increased its holdings in Johnson & Johnson by 1.8% in the fourth quarter. Live Oak Private Wealth LLC now owns 6,743 shares of the company’s stock valued at $975,000 after buying an additional 116 shares during the last quarter. Global X Japan Co. Ltd. raised its stake in Johnson & Johnson by 17.7% during the fourth quarter. Global X Japan Co. Ltd. now owns 3,178 shares of the company’s stock valued at $460,000 after buying an additional 478 shares in the last quarter. Prairie Wealth Advisors Inc. lifted its holdings in Johnson & Johnson by 2.8% during the 4th quarter. Prairie Wealth Advisors Inc. now owns 3,061 shares of the company’s stock worth $443,000 after buying an additional 84 shares during the last quarter. Finally, Beese Fulmer Investment Management Inc. grew its position in shares of Johnson & Johnson by 0.7% in the 4th quarter. Beese Fulmer Investment Management Inc. now owns 125,953 shares of the company’s stock worth $18,215,000 after acquiring an additional 869 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on JNJ shares. Bank of America reduced their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company reduced their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Stifel Nicolaus cut their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Finally, Leerink Partners lowered their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Stock Performance

JNJ stock opened at $154.22 on Tuesday. The company has a market capitalization of $371.31 billion, a P/E ratio of 23.19, a PEG ratio of 2.46 and a beta of 0.52. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a 50-day simple moving average of $147.42 and a 200 day simple moving average of $156.08. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the firm posted $2.29 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.22%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.